Navigation Links
Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up
Date:7/31/2014

PORTOLA VALLEY, Calif., July 31, 2014 /PRNewswire/ -- Rogne Bioscience, a privately-held biotechnology company based in San Francisco Bay Area, has acquired a licence to anti-inflammatory peptides from Isis Innovation, the University of Oxford's commercialisation company. The potent anti-inflammatory activity of the peptides was discovered by Professor David Greaves at the University of Oxford's Sir William Dunn School of Pathology.

The company, which has raised over $1.5 million in seed financing, is developing a first-in-class, topical biologic to address the unmet need for a safe, effective, non-steroidal treatment for patients with mild to moderate psoriasis.

Tom Gadek, CEO of Rogne, said: "In Rogne's feasibility studies, we have been able to verify the anti-inflammatory activity of the peptide that was first published by Professor Greaves' lab. We have also demonstrated that the peptide can be formulated to penetrate human skin and, when applied topically, inhibits dermal inflammation in a dose-dependent manner in mice. We plan to complete a clinical proof of concept study to demonstrate activity in psoriasis patients."

Professor Greaves said: "Because the peptide will be applied to the skin, we expect to avoid the side-effects which trouble patients who use current injected or oral psoriasis drugs.

"Our peptide is also derived from a protein which is produced naturally by the human body and appears to play a role as the body's own off-switch for inflammation. 

"It's been really great that Isis Innovation have worked with us over the last five years to ensure that these important early steps in reaching the potential of this discovery have happened. We are also delighted to be working with Rogne Bioscience."

Rogne's Chief Medical Officer, Karl Beutner, MD said: "All the biologic drugs that we currently use for treating conditions such as psoriasis work by dampening down inflammation all over the body, not just in the skin where the disease occurs. As a result they all have general immunosuppressive side-effects such as increases in number and severity of infections."

The peptides are derived from the plasma protein chemerin and work by reducing the production of inflammatory signaling proteins called cytokines which play a central role in the body's response to infection and injury. They are also implicated in the excessive immune responses underlying inflammatory diseases. The peptides inhibit activated antigen presenting cells by reducing the production of inflammatory cytokines including IL-12/23, TNFalpha, RANTES, IL-6 and IL-1beta.

Isis has granted Rogne an exclusive, world-wide licence to the associated patents.

The initial work in Professor Greaves' lab investigating inflammation was funded by the British Heart Foundation in the context of possible novel anti-inflammatory treatments for cardiovascular disease.  Professor Jeremy Pearson, Associate Medical Director at the Foundation, said: "We are delighted that the research we funded has now led to a potential new anti-inflammatory treatment for psoriasis."

Media enquiries:
Renate Krelle
Isis Innovation Ltd
renate.krelle@isis.ox.ac.uk
T: +44(0)1865280867

Lena Wu
Rogne Bioscience, Inc.
info@rognebioscience.com

About Isis Innovation

Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.

Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 395 licenses and consulting agreements with clients in 21 countries. The Isis Enterprise innovation management consultancy works with university, government and industrial clients from offices around the world.

For updates on innovations from Oxford, follow Isis on LinkedIn and Twitter or subscribe at www.isis-innovation.com

About Rogne Bioscience

Rogne Bioscience is an early stage, San Francisco Bay area-based biotechnology company focused on bringing forward novel biological treatments for inflammatory diseases. Its first clinical program will target psoriasis. For more information, please visit www.rognebioscience.com.

About the British Heart Foundation

The British Heart Foundation is a publicly funded research charity that supports over 50% of the UK's academic cardiovascular research.

PR 137/1


'/>"/>
SOURCE Rogne Bioscience, Inc.; Isis Innovation Ltd
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
2. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
3. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
4. Oxford Finance Completes $271.4 Million Securitization Transaction
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Performance Materials and Biomet Microfixation Join Forces
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Oxford BioMedica Announces Update from ARVO 2013
9. Oxford University Press to publish BioScience journal starting in 2014
10. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
11. HistoRx Licenses Melanoma Assay from Yale University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):